Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 17/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 17/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 17/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 17/20 | 0.48 |
| ▸ | BACE1 | P56817 | 2/20 | 0.37 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5350872 | 0.79 | BACE1 (0.36) | PDE4APDE4BPDE4CPDE4DBACE1 | |
| SCHEMBL3362216 | 0.79 | BACE1 (0.58) | PDE4APDE4BPDE4CPDE4DBACE1 | |
| SCHEMBL3367165 | 0.78 | BACE1 (0.59) | PDE4APDE4BPDE4CPDE4DBACE1 | |
| SCHEMBL5535995 | 0.77 | PDE4A (0.44) | PDE4APDE4BPDE4CPDE4DBACE1 | |
| SCHEMBL3367313 | 0.76 | PDE4A (0.45) | PDE4APDE4BPDE4CPDE4DBACE1 | |
| SCHEMBL8265789 | 0.75 | DRD2 (0.43) | PDE4APDE4BPDE4CPDE4DBACE1 | |
| SCHEMBL8266027 | 0.74 | BACE1 (0.41) | PDE4APDE4BPDE4CPDE4DBACE1 | |
| SCHEMBL8265973 | 0.73 | BACE1 (0.44) | PDE4APDE4BPDE4CPDE4DBACE1 | |
| SCHEMBL1634699 | 0.73 | BACE2 (0.43) | PDE4APDE4BPDE4CPDE4DBACE1 | |
| SCHEMBL1634599 | 0.72 | BACE1 (0.39) | PDE4APDE4BPDE4CPDE4DBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232630-A1 | MACROCYCLE DERIVATIVES USEFUL AS INHIBITORS OF beta-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2007-10-04 | — | — | US | disclosed |
| WO-2007092839-A2 | MACROCYCLE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232630-A1 | MACROCYCLE DERIVATIVES USEFUL AS INHIBITORS OF beta-SECRETASE (BACE) | BACE2, BACE1, PSEN2 | PDE4A 2365/4885PDE4B 1501/4885PDE4C 1971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.